Related Experiment Videos
National Monthly Outpatient Claim-Recorded Lecanemab Drug Amount in Japan During Fiscal Year 2024
Takuya Omura1,2, Takahiro Kamihara3
1Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Abstract:
Nationwide claim-recorded lecanemab drug amount for outpatient administration within medical institutions increased from 1.05 million mg in April 2024 to 7.73 million mg in March 2025. Under a 60-kg scenario, these amounts corresponded to 807 and 5924 standardized monthly treatment-volume equivalents; these aggregate measures are not patient counts.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs
Drug Products: Biologics, Biosimilars and Interchangeables
Therapeutic Drug Monitoring: Drug Analysis Methods